BSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Boston Scientific Corp (BSX) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company has shown strong financial performance in its latest quarter and Congress trading data indicates positive sentiment, the technical indicators, insider selling trends, and ongoing legal challenges suggest caution. Additionally, the absence of proprietary trading signals further reduces the attractiveness of the stock for immediate purchase.
The MACD is positive and expanding, indicating bullish momentum. However, RSI is neutral at 50.898, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5), signaling potential downward pressure. Key support and resistance levels are Pivot: 69.937, R1: 71.431, and S1: 68.443. Overall, the technical indicators suggest a mixed to bearish outlook.
Strong financial performance in Q4 2025, with revenue up 15.90% YoY and net income up 18.94% YoY.
Congress trading data shows significant purchases by Congress members, indicating confidence in the stock.
Analysts maintain a Buy rating, with a positive outlook on upcoming CHAMPION-AF trial results.
Insider selling has increased by 755.62% over the last month, signaling potential lack of confidence from company insiders.
Class action lawsuits and legal investigations related to misleading statements and financial health concerns.
Recent price target reductions by multiple analysts, reflecting moderated growth expectations and increased scrutiny on growth drivers.
In Q4 2025, Boston Scientific reported strong growth: Revenue increased by 15.90% YoY to $5.29 billion, net income rose by 18.94% YoY to $672 million, EPS grew by 18.42% YoY to $0.45, and gross margin improved by 3.76% to 65.38%. These figures highlight robust financial health and operational efficiency.
Analysts maintain a Buy rating despite recent price target reductions. The average price target is in the range of $90-$96, reflecting a positive long-term outlook but moderated expectations due to slower growth in key markets and increased competition.
